Compare MLP & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLP | TLSI |
|---|---|---|
| Founded | 1909 | 2010 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Real Estate | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.8M | 270.2M |
| IPO Year | 2010 | 2020 |
| Metric | MLP | TLSI |
|---|---|---|
| Price | $15.17 | $4.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | 10.7K | ★ 294.1K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $19,457,000.00 | ★ $45,151,000.00 |
| Revenue This Year | N/A | $17.65 |
| Revenue Next Year | N/A | $40.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 68.24 | 53.41 |
| 52 Week Low | $13.84 | $2.20 |
| 52 Week High | $19.92 | $7.95 |
| Indicator | MLP | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 32.12 | 33.83 |
| Support Level | $15.14 | $3.64 |
| Resistance Level | $16.45 | $4.47 |
| Average True Range (ATR) | 0.51 | 0.35 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 44.71 | 1.15 |
Maui Land & Pineapple Co Inc is a landholding and operating parent company that owns land and commercial property on the island of Maui, Hawaii. The Company puts its assets into productive use by planning, managing, developing, and selling residential, resort, commercial, agricultural, and industrial real estate. Its segments include land development and sales, which cover land planning, entitlement, development, construction, and sales of land assets; leasing, which generates revenue from real property leasing, license fees and royalties, and includes maintenance of real estate assets, conservation activities, and management of water systems in West and Upcountry Maui; and resort amenities, which include a membership program offering benefits within the Kapalua Resort.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.